- Any clinically significant malabsorption condition (eg, gastrectomy, bowel resection).
- Total 14C radioactivity measured in plasma exceeding 11 mBq/mL
- History of tuberculosis or active or latent or inadequately treated infection,
positive QuantiFERON®?TB Gold test
- Use of tobacoo/nicotine containing products 3-m prior to dosing or positive urine
cotinine test
- Use of herbal supplements within 28 days prior to the first dose of study medication
- Use of prescription or nonprescription drugs (including vitamins and dietary
supplements) within 7 days or 5 half?lives (whichever is longer) prior to the first
dose of study medication. As an exception, acetaminophen may be used at doses of 1
g/day. Limited use of non?prescription medications that are not believed to affect
subject safety or the overall results of the study may be permitted on a case?by?case
basis following approval by Pfizer
- Inability to have at least one bowel movement every 2 days on average eGFR of mL/mim/1.73 m2 based on MDRD equation
- Have been vaccinated with live or attenuated live vaccine within the 6 weeks prior to
the first dose of investigational product, or expects to be vaccinated with these
vaccines during study treatment, or within the 6 weeks following the last dose of
investigational product.